GSA Capital Partners LLP lifted its stake in Regulus Therapeutics Inc (NASDAQ:RGLS) by 44.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 203,815 shares of the biopharmaceutical company’s stock after acquiring an additional 63,100 shares during the period. GSA Capital Partners LLP owned approximately 0.20% of Regulus Therapeutics worth $255,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the company. Royal Bank of Canada grew its stake in shares of Regulus Therapeutics by 12.1% in the second quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock worth $182,000 after acquiring an additional 19,934 shares during the last quarter. FMR LLC grew its stake in shares of Regulus Therapeutics by 0.5% in the second quarter. FMR LLC now owns 7,977,349 shares of the biopharmaceutical company’s stock worth $7,862,000 after acquiring an additional 37,489 shares during the last quarter. Quantitative Investment Management LLC acquired a new stake in shares of Regulus Therapeutics in the second quarter worth $103,000. Goldman Sachs Group Inc. grew its stake in shares of Regulus Therapeutics by 189.1% in the second quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock worth $363,000 after acquiring an additional 240,890 shares during the last quarter. Finally, Victory Capital Management Inc. acquired a new stake in Regulus Therapeutics during the third quarter worth $347,000. Institutional investors and hedge funds own 59.39% of the company’s stock.

Shares of Regulus Therapeutics Inc (RGLS) opened at $1.18 on Thursday. Regulus Therapeutics Inc has a 52 week low of $0.79 and a 52 week high of $2.60. The company has a quick ratio of 6.77, a current ratio of 6.77 and a debt-to-equity ratio of 0.41. The company has a market cap of $122.67, a price-to-earnings ratio of -0.88 and a beta of 1.55.

A number of equities research analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, September 19th. Wedbush reiterated an “outperform” rating and set a $4.00 price target on shares of Regulus Therapeutics in a research note on Monday, December 11th. Leerink Swann assumed coverage on shares of Regulus Therapeutics in a research note on Friday, January 5th. They set an “outperform” rating and a $2.00 price target on the stock. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Regulus Therapeutics in a research note on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company’s stock. Regulus Therapeutics presently has an average rating of “Hold” and a consensus target price of $2.46.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/regulus-therapeutics-inc-rgls-stake-boosted-by-gsa-capital-partners-llp/1802486.html.

Regulus Therapeutics Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Institutional Ownership by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.